Introduction
Although the existence of a dose-response relationship in anti-cancer chemotherapy of solid tumours has long been suggested on the basis of experimental and preclinical models [1] , the clinical validation of these theoretical concepts still requires clinical validation.
As long ago as 1981, Bonadonna and several others studied retrospective surveys in breast cancer and suggested the importance of dose and dose-intensity (dose per unit of time) in both adjuvant therapy and metastatic disease [2, 3] . While it is true that the statistical and methodological bias inherent in several of these surveys had to be considered with caution, they nevertheless had the merit of inciting the design of controlled, prospective studies. The most recent results obtained have made it possible to show the importance of the threshold dose concept [4] [5] [6] , although they have yet to demonstrate a true dose-response relationship.
The first prospective studies to assess the notion of dose and/or dose-intensity in metastatic breast cancer date from the 1980s and, in most cases, did not demonstrate a significant advantage in terms of disease-free survival or overall survival, despite an increase in response rates [7] . It should, however, be emphasized that the dose increase in these studies ranged from 1.25 to 2.0, that most of them did not involve haematopoietic support, and that the only two studies which were positive in terms of survival included small patient populations and control groups which could be considered as receiving an insufficient dose [5, 6] .
The CALGB (Cancer and Leukemia Group B) recently published Tesults of a randomized trial in the adjuvant setting comparing three schedules of (FAC) 5-FU, adriamycin, cyclophosphamide [4] . Dose levels and dose-intensity were similar to the studies mentioned above, and no haematopoietic support was given. With a current follow-up of five years, this trial has confirmed the concept of a threshold-effect, a significant advantage being observed in terms of disease-free survival and overall survival in the two 'intensified' groups when compared with the moderate dosage group. However, the latter group could be considered as under-dosed (5-FU: 300 mg/m 2 , dl-d8; adriamycin: 30 mg/m 2 , dl; cyclophosphamide: 300 mg/m 2 , dl; 4 cycles repeated every 28 days). The most striking results, suggesting the existence of a true dose-response effect in breast cancer, have in fact been obtained in intensification studies involving haematopoietic support (autologous bone marrow transplantation with or without haematopoietic growth factors, or, peripheral blood stem cell transplantation) with the dose increase ranging from 5 to 10. Most of these studies were conducted between 1985 and 1990 in patients with advanced metastatic disease and/or refractory to conventional chemotherapy; high response rates of about 60% were obtained, with complete response rates of 15% to 20%. However, the median duration of response was short and no significant improvement could be seen in terms of survival [8, 9] . Nonetheless, insofar as these trials suggested the possibility of overcoming acquired or intrinsic resistance by dose intensification, they validated the concept of a dose-response effect in breast cancer, at least in terms of the clinical response rate endpoint. Spectacular advances have also been achieved in recent years in the use of haematopoietic support, particularly with the development of growth factors and peripheral blood stem cell transplantation. While a significant reduction in the morbidity and the mortality linked to chemotherapy-induced haematological toxicity is still awaited, these trials have encouraged numerous teams to study dose intensification in the setting of greatest potential interest, in other words, first line chemotherapy in metastatic breast cancer, high risk breast cancer including cases with massive axillary node involvement (>6-10), locally advanced breast cancer and inflammatory breast cancer [10] .
Dose intensification in metastatic disease
The first trials of dose intensification with autologous bone marrow transplantation in metastatic breast cancer date from the late 1980s. They mainly consisted of limited surveys of patients refractory to conventional chemotherapy and receiving second, third or fourth line therapy. Despite notable therapeutic toxicity (10% to 20% of toxic deaths), impressive response rates ranging from 40% to 80% were reported, with complete responses in 15% to 20% of cases [2, 11] . However, the responses obtained were generally shortlived and long term survival was exceptional.
Nonetheless, these pilot and feasibility studies enabled validation of the concept of dose intensification in terms of response, analysis of the potential efficacy and toxicity of intensification agents and the principal factors causing relapses. Analysis of relapses showed that they mainly occurred at the site of the primary tumour, particularly in the case of large tumour mass, prior to intensification. Thus, together with experience acquired in dose intensification for haematological malignancies, and particularly non-Hodgkin's lymphoma, these results led the same investigators to propose dose intensification in chemo-sensitive patients earlier in the evolution of the disease, but after tumour debulking. Most of the resulting trials were initiated in the early 1990s with induction chemotherapy and the first data are now available. Table 1 summarises the principal trials published on the subject of consolidated intensification therapy in metastatic disease. Results are generally available in abstract form and report on relatively short median follow-up periods [11] [12] [13] [14] [15] [16] [17] [18] .
Dose intensification in consolidation after induction chemotherapy
Emphasis must be laid on the heterogeneity of the selected population in these intensification trials.
Most patients were young (<55 years), premenopausal, in good general health, receiving first-line chemotherapy and with a low initial tumour mass (fewer than 2 or 3 invaded sites). Patients presenting with involvement of the bone or the medulla were usually excluded. Furthermore and significantly, the majority of these studies did not specify the principal predictive factors existing in the metastatic setting, such as presence and number of visceral -and notably hepatic -sites, initial hormone receptor status, existence of prior adjuvant chemotherapy (in particular with, or without, anthracyclines) and the interval between initial diagnosis and the first evidence of metastatic disease.
A factor common to all trials however was the inclusion of patients considered as hormone-refractory, i.e. patients with negative hormone receptors, or who had progressed after first-line hormone therapy. Trials also varied greatly in terms of preintensification protocols for induction chemotherapy. When specified, these regimens were difficult to compare on the basis of type, intensity and duration. Post induction response levels range from 60% to 100%, depending on the author, complete responses being observed in 15% to 50% of patients: quite spectacular results which clearly demonstrate the prior selection inherent in this type of trial.
Analysis of these results is equally problematical due, once more, to the heterogeneity of the trials. Although most of the investigators dose-intensified patients considered to be chemo-sensitive after induction (on the basis of a complete or a partial response), some of them also proposed intensification in patients who had stabilised [14, 15] . Furthermore, the exact percentage of the entire patient population receiving dose intensification is rarely specified. This essential factor makes it impossible to assess feasibility. The following observations can be made:
-a conversion rate from partial response to complete response ranging from 6% to 55% (mean 30%), after dose intensification, thus corroborating the notion of a dose-effect relationship in terms of response rate; -complete response rates averaging 50% and ranging from 34% to 75%; -a 'toxic' death rate (difficult to compare because of differing intensification regimens, but not to be overlooked) which ranged from 0% to 20%. However, these rates have fallen in more recent trials, where haematopoietic support has included peripheral blood stem cells and growth factors, either alone or associated with autologus bone marrow transplantation, and where the average treatment-related mortality rate is about 5% to 10%. These results are probably a consequence of a significant reduction in the duration of aplasia and hospitalisation, and thus in related toxicity. However, without major prospective trials, it is impossible to analyse the specific contribution of growth factors and stem cells to this apparent reduction in toxicity; -duration of response of 6 to 18 months and median survival of 12 to 24 months, not significantly differing overall from the results obtained with conventional chemotherapy.
Comparative survival analysis
Although the current follow-up periods are relatively short, analysis shows a mean disease-free survival of 17% to 25% and an overall survival rate ranging from 20% to 50% at two years. In view of the selection criteria for inclusion in these trials and the fact that these patients generally represented fewer than 10% of all metastatic patients, analysis of the survival rates reported is difficult, as is their comparison with historical studies. However, an overall analysis seems to indicate that, in the refractory setting and despite obtaining complete responses in 10% to 35% of cases, dose intensification as it currently exists will not enable an improvement in disease-free survival or overall survival rates over those achieved with conventional chemotherapy. 8 (20) 0 1 (3) 6 (8) 10 (22) 1 (4) 3 (12) 3 (5) Results after CR (%)
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39 (100) 24 (100) 29 (100) 61 (79) 30 ( As consolidation in first line therapy, the disease-free survival rate at two years appears to be around 20% to 30%, with an average overall survival rate of 40% to 50%. At three years, the results show a disease-free survival rate of 20% to 25% and overall survival rate of 25% to 40%; these levels appeared to be maintained at five years [18, 19] . The most interesting results concern those patients who were in complete remission (or NED) prior to treatment intensification, and experienced genuine long term benefits with a 30% to 50% disease-free survival rate at five years [19] . With respect to a comparison with conventional chemotherapy, reference must be made to Eddy [20] whose compilation of the principal trials involving conventional chemotherapy in metastatic disease produced an overall survival rate of 39% at two years and 25% at three years. Similarly, in 1988 Hortobagyi and his colleagues reported the long term results for the entire patient group in the FAC trial. Among the 1424 patients treated with the FAC protocol as first line chemotherapy, 5 and 10 year progression-free survival rates were 12.5% and 9%, respectively, in complete responders and 2% and 1% for non complete responders [21] .
In conclusion, although dose intensification in metastatic disease does not currently appear to provide a significant advantage in terms of survival and diseasefree survival at two or three years, we can hope for disease-free survival and overall survival rates close to 30% at five years in the small and highly selected group of patients who were in complete remission prior to intensification [18, 19] . These promising results have given rise to several prospective trials (in progress or planned) which will compare conventional chemotherapy with a dose intensification protocol in chemosensitive patients. Furthermore, since the principal predictive factor for durable disease free survival following intensification appears to be the achievement of a complete response after induction therapy, a number of investigators are currently proposing dose intensification only in those patients with no objective evidence of disease after either induction chemotherapy or locoregional treatment [19] .
Dose intensification in high-risk breast cancer
Although the results obtained in metastatic disease are preliminary and open to debate, they have been judged sufficiently interesting by a number of authors to propose dose intensification in high-risk patients, and particularly in breast cancer patients with metastatic nodal involvement. The definition of 'high-risk' in the context of breast cancer remains controversial, but three situations can be identified: intensification of adjuvant therapy in patients with massive axillary node involvement, intensification as an integral part of a multimodality strategy for inflammatory breast cancer and intensification in certain locally-advanced breast cancers.
Intensification of adjuvant therapy in patients with massive axillary node involvement f>6to 10 nodes)
Breast cancer patients with more than 10 axillary nodes at the time of surgery unquestionably represent a highrisk population. Major retrospective studies without adjuvant therapy have shown disease-free survival (DFS) at five years to be less than 35%, with a persistent risk of relapse; DFS at ten years reaches only 20%-25% [22, 23] . Furthermore, results with conventional adjuvant chemotherapy in this type of high-risk patient do not appear to have fundamentally modified the prognosis. In addition, recent preliminary results of adjuvant chemotherapy regimens considered to be semi-intensive (dose multiplication factors of 1 to 2.5), provide no indication of an improved prognosis [4, 24] .
In the light of these disappointing results with conventional or semi-intensive chemotherapy in breast cancer patients with severe nodal involvement, several groups have tested dose intensification in this group of high-risk patients. Table 2 summarises the principal trials [25] [26] [27] [28] [29] [30] .
Note should be made of the selection criteria applied in this type of trial, most of which concerned patients presenting massive axillary involvement (stage n, N + > 6-10) and those with locally advanced stage IH breast cancer where the nodal involvement had not been specified accurately, if at all. Under these circumstances, only the studies by Gianni and Peters can be considered as homogeneous, since they only included patients with stage II disease and N + > 10 [29, 30] . Toxicity-related death rates were usually lower than 5%, which is less than results reported in metastatic disease, and indicates the selection of populations which were younger, not pre-treated, in better general health and receiving haematopoietic support with peripheral blood stem cells, associated to a greater or lesser extent with autologous bone marrow grafts. Although follow-up periods are relatively short, the results seem very encouraging. Peters and his group, for example, who recruited the largest number of patients, saw a five-year DFS rate of 64% with overall survival of 75% [30] . The results of other trials also appear very promising, with DFS ranging from 60% to 100% for median follow-up periods of 20 to 50 months (range: 6-12 months) [25] [26] [27] [28] [29] [30] .
By comparison with historical studies and despite the bias inherent in this type of analysis, it seems that dose intensification in this indication can significantly improve progression-free survival rates, as results show a shift from 30% to 40% at five years under conventional chemotherapy [4, 22] to more than 60% in intensification studies [29, 30] .
It will be necessary to conduct randomized, prospective trials before formal conclusions can be drawn in this respect: these are planned or already under way. However, it should be remembered that if the definition of high-risk in adjuvant therapy remained the same as at present, that is more than 10 nodes, this strategy would only be relevant for 10% of breast cancer patients and for 20% of N + cancers. Furthermore, certain patients within this population (from 20% to 40% according to different historical studies) appear to be cured after conventional chemotherapy, thus emphasizing the importance of the toxic risk linked to intensification. Urgent steps must thus be taken to define other prognostic and/or predictive factors which would enable the improved selection of patients likely to benefit from this type of strategy. Several recent studies appear to have confirmed the prognostic role of oncogene C-ERB-2 overexpression in adjuvant and conventional chemotherapy [31] [32] [33] . For instance, the CALGB study made it possible to note that the patients deriving the most benefit from semi-intensive chemotherapy ('intensified' FAC) were those who overexpressed C-ERB-2 [33] .
Similarly, two other studies have reported the lack of clear benefits from conventional CMF therapy in patients over-expressing C-ERB-2, which could indicate either an intrinsic resistance to CMF, or the potential interest of anthracyclines and/or a more intensive regimen for such patients [31, 32] . In any case, current prospective studies of intensification programmes should include an experimental biological study to detect any predictive factors, notably the over-expression of C-ERB-2 and the relative importance of the S phase and/or the histological grade. [18, [38] [39] [40] [41] . Prospective studies are planned or under way to define more clearly the potential advantages of dose intensification in this indication.
Locally advanced breast cancer
A more complex situation prevails in the case of locally advanced breast cancers (stages Ula and HTb, excluding the inflammatory forms); results with intensification are even more preliminary. In this patient group, which is heterogeneous in terms of prognosis, it is clear that conventional systemic chemotherapy integrated with locoregional treatment has enabled a reduction in the rate of metastatic evolution and, in certain studies, an increase in DFS. However, a definitive advantage in terms of overall survival has not so far been demonstrated [42] . Results from several pilot studies on intensification are now becoming available, but it is impossible to draw any clear conclusion because of the very limited number of patients under treatment, the heterogeneity of inclusion criteria (inflammatory forms or cancers with massive nodal involvement) and the very short median follow-up periods (10 to 36 months). It is the heterogeneity of this patient group which makes it absolutely essential to define initial prognostic factors as clearly as possible so as to identify any advantages of dose intensification integrated into a combined treatment.
Dose intensification in inflammatory and/or locally advanced breast cancer patients

Inflammatory breast cancer
There is no doubt that chemotherapy integrated in a multiple treatment strategy for inflammatory breast cancer has enabled a clear improvement in the prognosis for this disease, with a five-year survival rate which has risen from less than 5% after locoregional treatment alone to more than 40% to 50% with systemic chemotherapy. However, 50% to 60% of these patients will continue to die as a result of metastatic disease [34] .
Moreover, it now appears clear that clinical response to an induction regimen and the pathological response level (complete histological remission) are the principal prognostic and/or predictive factors in inflammatory breast cancer [35, 36] . These responses seem to be closely linked to dose and dose intensity, and may thus be dose-dependent [35, 37] . Since inflammatory breast cancer is a highly chemosensitive disease, it may therefore be a good candidate for study of the dose-effect concept. For this reason, several authors have tested dose intensification in inflammatory breast cancer, and obtained very encouraging preliminary results. This therapeutic approach enables a DFS rate at three years of more than 60%, thus giving hope for a significant improvement in overall survival at five years (Table 3 )
Future perspectives
The feasibility of myeloablative dose intensification in breast cancer has already been demonstrated. Toxic death rates from early trials may have been high but they now appear to have declined steadily to between 0% and 5%, which can be considered as acceptable in a high-risk, fatal disease. Conventional chemotherapy still carries a toxic death rate of around 1% and current, prospective trials will enable a clearer distinction between the toxicities caused by these two strategies, and render any risk more acceptable if a therapeutic benefit has been demonstrated.
Today, dose intensification in the adjuvant therapy of high-risk breast cancer seems to be the most beneficial strategy, with a DFS rate at three years higher than 70%. Theoretically, this strategy should develop and become equally promising in inflammatory breast cancer. Any benefit of dose intensification in the consolidation of metastatic breast cancer seems to be restricted to a highly selected sub-group of chemosensitive patients in complete remission after induction, and is yet to be demonstrated. In terms of the development of intensification strategies in the area of breast cancer, it is important to recall the major selection bias inherent in the results of these phase II trials, with particular emphasis being laid upon the small number of subjects included, the exclusion of micrometastatic disease (for adjuvant intensification studies), the very short follow-up period before certain results have been published, the type of publication (particularly abstracts) with an obvious lack of basic prognostic data, and finally, the known bias of publications toward positive results. This type of treatment strategy is developing in two principal directions: toward a reduction in therapeutic toxicity and the optimization of intensification regimens.
Reduction of therapeutic toxicity
Although early dose intensification trials incorporating haematopoietic support included autologous bone marrow transplantation (ABMT), associated to a greater or lesser extent with the use of growth factor (HGF), the current trend is for ABMT to be replaced by the transfusion of peripheral blood stem cells (PBSC) with or without growth factor support [43, 44] . However, in the context of dose intensification for breast cancer support, data are still awaited concerning the relative benefits of PBSC ± HGF or ABMT ± HGF in terms of long-term medullary reconstitution, duration of aplasia, morbidity and cost. In the absence of prospective studies, indirect or historic comparisons appear to indicate a reduced duration of aplasia and hospitalisation with ABMT ± HGF [8, 9] . However, both the intensification regimens and the populations studied vary greatly, and only controlled trials will make it possible to reach valid conclusions.
The use of HGF after ABMT now seems to be accepted practice insofar as a significant reduction in the duration of aplasia has been demonstrated [44] ; the benefits of HGF after PBSC remain, however, subject to controversy [45] . In parallel, investigations are under way into the use of early progenitors (CD34 + ) which could offer the double advantage of more rapid haematological reconstitution and lower tumour contamination [46, 47] .
Optimisation of intensification regimens
Authors of the earliest trials using ABMT as the sole haematopoietic support recommended a single intensification only (single pulse of very high-dose chemotherapy); however, numerous theoretical concepts and preclinical data on tumour resistance and kinetics argue in favour of sequential and/or alternating strategies [48] .
The advent of HCG and PBSC may, at least in theory, enable the close, sequential administration of intensification regimens (repeated or alternating) with a significant increase in dose and dose intensity. In addition, several investigators are now moving toward new methods for the intensification of dose and dose intensity:
-repeated sequential administration of very highdose chemotherapy (double intensification) [17] ; -alternating sequential administration of high-dose chemotherapy under regimens without crossresistance [49] .
Finally, certain groups are trying to introduce new active drugs into their intensification regimens, a particular example being very high dose taxol [50] . In parallel, other groups are proposing immediate intensification (without induction) so as to diminish the theoretical risk of chemotherapy-induced resistance [51] . For the most part, such attempts to optimise intensification protocols are only at the feasibility stage and the results are far too preliminary to assess any advantages in terms of anti-tumour response and/or survival when compared to a single intensification supported by ABMT and/or PBPC with or without HGF.
Nonetheless, whatever the direction taken by current research in the field of myeloablative dose intensification supported by ABMT and/or PBPC with or without HGF, there remains an essential question to which only new, prospective trials can provide an answer: is myeloablative dose intensification more effective than the sub-ablative intensification of dose and dose intensity supported by HGF alone? Certainly the choice of sub-ablative intensification with HGF support alone represents an attractive strategy, as it places emphasis on dose-intensity intensification rather than on dose, it appears to be less costly and is probably less toxic. This approach is currently under study and the very preliminary results seem encouraging [52] .
Conclusion
Dose intensification strategies are currently undergoing much change and different approaches to this problem are providing some very encouraging results, principally in the first-line consolidation of chemosensitive metastatic breast cancer, but also in consolidation adjuvant therapy in high-risk patients and potentially in inflammatory and locally advanced breast cancer. The small number of prospective trials currently under way will form the basis for a clearer definition of the potential advantages of this type of strategy. However, equal emphasis must be laid on the need to initiate controlled trials which will compare myeloablative dose intensification with sub-ablative intensified protocols and thus define the exact role of dose and dose intensity, variables which are not being studied separately in the majority of current trials.
